Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ASP015K

- PMLiVE

Astellas and Cullgen announce protein degrader partnership worth up to $1.9bn

The companies will use Cullgen’s protein degradation platform to discover multiple candidates

- PMLiVE

Janssen shares positive phase 3 results for cilta-cel in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

Janssen shares positive phase 3 results for erdafitinib in bladder cancer

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Amgen reports positive results for inflammatory disease drug Otezla in psoriatic arthritis

The inflammatory condition is estimated to affect nearly 38 million people worldwide

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

- PMLiVE

Astellas Pharma’s non-hormonal menopause drug granted FDA approval

Vasomotor symptoms affect up to 80% of menopausal individuals in the US

- PMLiVE

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

The candidates have shown the potential to treat forms of non-Hodgkin’s lymphoma

- PMLiVE

Janssen’s Akeega receives EC approval for metastatic prostate cancer

The authorisation marks the first worldwide approval of the niraparib-based combination

- PMLiVE

Janssen and AbbVie’s Imbruvica combination recommended by NICE for leukaemia

Approximately 3,800 people in the UK are diagnosed with chronic lymphocytic leukaemia each year

- PMLiVE

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

The treatment is already approved in the US for three disease states of prostate cancer

- PMLiVE

Results for Astellas’ non-hormonal menopause drug published in The Lancet

Symptoms such as hot flashes and night sweats are the most common symptoms of menopause

- PMLiVE

Janssen’s single tablet combination shows promise in phase 3 PAH study

Around 500 to 1,000 cases of pulmonary arterial hypertension are diagnosed each year in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links